Capricor Therapeutics (NASDAQ:CAPR) CFO Sells $732,158.00 in Stock

Capricor Therapeutics, Inc. (NASDAQ:CAPR) CFO Anthony Bergmann sold 24,100 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $30.38, for a total transaction of $732,158.00. Following the completion of the transaction, the chief financial officer owned 11,223 shares in the company, valued at $340,954.74. This represents a 68.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Anthony Bergmann also recently made the following trade(s):

• On Monday, June 22nd, Anthony Bergmann sold 500 shares of Capricor Therapeutics stock. The shares were sold at an average price of $30.00, for a total transaction of $15,000.00.
• On Wednesday, June 24th, Anthony Bergmann sold 400 shares of Capricor Therapeutics stock. The stock was sold at an average price of $30.00, for a total transaction of $12,000.00.
• On Friday, May 1st, Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock. The stock was sold at an average price of $31.70, for a total transaction of $792,500.00.

Capricor Therapeutics Trading Up 0.6%

CAPR stock opened at $23.21 on Friday. The stock has a market capitalization of $1.34 billion, a price-to-earnings ratio of -10.00 and a beta of 0.42. The firm’s 50-day moving average price is $29.11 and its two-hundred day moving average price is $28.31. Capricor Therapeutics, Inc. has a 12-month low of $4.30 and a 12-month high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR) last posted its earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04). Equities analysts predict that Capricor Therapeutics, Inc. will post -0.49 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Royal Bank of Canada boosted its position in shares of Capricor Therapeutics by 12.4% in the 4th quarter. Royal Bank of Canada now owns 5,040 shares of the biotechnology company’s stock worth $146,000 after purchasing an additional 557 shares in the last quarter. KBC Group NV bought a new position in Capricor Therapeutics during the 1st quarter valued at approximately $44,000. ACT Capital Management LLC purchased a new position in Capricor Therapeutics during the fourth quarter valued at $43,000. Nuveen LLC boosted its holdings in Capricor Therapeutics by 2.1% in the fourth quarter. Nuveen LLC now owns 90,951 shares of the biotechnology company’s stock worth $2,625,000 after acquiring an additional 1,878 shares in the last quarter. Finally, State of Wyoming boosted its holdings in Capricor Therapeutics by 76.0% in the fourth quarter. State of Wyoming now owns 4,429 shares of the biotechnology company’s stock worth $128,000 after acquiring an additional 1,913 shares in the last quarter. Institutional investors own 21.68% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently issued reports on CAPR. Cantor Fitzgerald set a $62.00 target price on Capricor Therapeutics and gave the company an “overweight” rating in a research note on Friday, March 13th. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price target on shares of Capricor Therapeutics in a research note on Wednesday, May 13th. Piper Sandler reiterated an “overweight” rating and issued a $58.00 price target (up from $45.00) on shares of Capricor Therapeutics in a report on Friday, March 13th. Roth Mkm reissued a “buy” rating and set a $38.00 price objective on shares of Capricor Therapeutics in a research report on Friday, May 15th. Finally, B. Riley Financial upped their price objective on shares of Capricor Therapeutics from $50.00 to $63.00 and gave the stock a “buy” rating in a report on Friday, March 13th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $53.67.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.